05-05-06

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

E Mo,		Application Number		10/656,895
TRANSMITTAL FORM		Filing Date		September 5, 2003
		First Named Inventor		Scott A. Waldman
		Art Unit		1643
(to be used for all correspondence after	initial filing)	Examiner Name		Rawlings, Stephen L.
Total Number of Pages in This Submiss		Attorney Docket Numb	ey Docket Number TJU0007-103	
	ENCLO	SURES (check all that ap	ply)	
Fee Transmittal Form	Drawing(s			After Allowance Communication to TC
Fee Attached	Licensing	-related Papers	_	Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Petition			Appeal Communication to TC Appeal Notice, Brief, Reply Brief)
After Final	- Land	Convert to a al Application		Proprietary Information
		Attorney, Revocation f Correspondence	□s	status Letter
Extension of Time Request	Terminal [rminal Disclaimer		Other Enclosure(s) please identify below):
Express Abandonment Request CD, Numb		■		SB08a (1p.); (2) References Cited, (2) rences Enclosed.
Supplemental Information Disclosure Statement	☐ Landscape Table on CD			
Certified Copy of Priority Document(s)	Remarks EXPRESS MAIL LABEL NO: EV770975215US			
Reply to Missing Parts/	DATE OF DEPOSIT: 5/3/2006			
Incomplete Application Reply to Missing Parts under 37 CFR1.52 or 1.53	EV770975215US			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Cozen O'Connor Signature Printed Name Mark DeLuca Date Mg 3 2006 Reg. No. 33,229

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on the date shown below

iexantina, VA 22313-1430 th the trate shown below.					
Signature					
Typed or printed name		Date			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 0 9 200 In Re

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scott A. Waldman et al.

Serial No.: 10/656,895

Group Art Unit: 1643

Filing Date: September 5, 2003

Examiner: Rawlings, Stephen L.

For: Compositions that specifically bind to colorectal cancer cells and methods of using

the same

Express Mail Label No. EV770975215US Date of Deposit: 5/3/2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

Ш	within three months of the filing date of the patent application.
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
\boxtimes	before the mailing date of a first Office Action on the merits.
	before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114.

	after the mailing date of a first Office Action on the merits or after the filin of a Request for Continued Examination under § 1.114, but before the mailin date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:		
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);	
		or	
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or	
		No fee is owed by the applicant(s).	
	Staten Final C.F.R	cordance with 37 C.F.R. § 1.129(a), this Information Disclosure nent is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.	
	Notice with, Staten	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a e of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously the payment of the Issue Fee, and accordingly is accompanied by the nent under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 . §1.17(p).	
\boxtimes	-	s of the references listed on the attached PTO Form SB/08B, formerly as PTO Form 1449, are enclosed.	
EXCE	EPT TH	IAT:	
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.	
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) @@ for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.	
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	
Staten	nent un	der 37 C.F.R. § 1.97(e)	
	in the foreign	Information Disclosure Statement was cited in a communication from a patent office in a counterpart foreign patent application not more than months prior to the filing of the Information Disclosure Statement.	

Stater	ment under 37 C.F.R. § 1.704(d)
	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.
Fees	
\boxtimes	No Fee is owed by the applicant(s).
	The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.
Metho	od of Payment of Fees
	Attached is a check in the amount of \$ This form is submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
\boxtimes	No fee or Statement is required under 37 C.F.R. § 1.97(b).
:	Respectfully submitted,

Dated: May 3, 2006 COZEN O'CONNOR, P.C. 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 - Telephone (215) 665-2013 - Facsimile

Mark DeLuca

Registration No. 33,229

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute to the B/PTO

MAY 0 3 2008

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	•		
Sheet	1	of	1

	Complete if Known	
Application Number	10/656,895	
Filing Date	September 5, 2003	
First Named Inventor	Scott A. Waldman	
Art Unit	1643	
Examiner Name	Rawlings, Stephen L.	
Attorney Docket Number	TJU0007-103	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	1	Pearlman et al., "A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells," <i>Dig. Dis. Sci.</i> (2000) 45(2):298-305.		
	2	Waldman et al., "Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro," Cancer Epidemiol. Biomarkers Prev. (1998) 7(6):505-514.		
			-	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.